Abrilumab (AMG 181) in Adults With Moderate to Severe Crohn's Disease
Status:
Completed
Trial end date:
2018-04-10
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to evaluate the efficacy of abrilumab as measured by
the proportion of participants achieving Crohn's Disease Activity Index (CDAI) remission
(CDAI < 150) after treatment for 8 weeks.